Analysts Set Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) PT at $33.67

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have been given a consensus recommendation of “Buy” by the eleven analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $33.6667.

Several equities research analysts have commented on the stock. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Scotiabank assumed coverage on Teva Pharmaceutical Industries in a report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 price objective for the company. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Sunday, January 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday. Finally, Barclays started coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target for the company.

Insider Activity

In other news, VP Richard Daniell sold 115,468 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the sale, the vice president directly owned 48,384 shares of the company’s stock, valued at $1,387,653.12. This represents a 70.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the transaction, the insider owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. This represents a 80.41% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 622,060 shares of company stock worth $17,076,965. 0.55% of the stock is currently owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several large investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its holdings in Teva Pharmaceutical Industries by 3.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company’s stock valued at $382,000 after purchasing an additional 379 shares in the last quarter. Howard Bailey Securities LLC grew its holdings in shares of Teva Pharmaceutical Industries by 3.5% during the third quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock worth $292,000 after buying an additional 494 shares in the last quarter. ASR Vermogensbeheer N.V. raised its position in shares of Teva Pharmaceutical Industries by 1.6% in the third quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock valued at $645,000 after buying an additional 515 shares during the last quarter. CIBC Private Wealth Group LLC raised its position in shares of Teva Pharmaceutical Industries by 15.5% in the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock valued at $81,000 after buying an additional 540 shares during the last quarter. Finally, Retirement Planning Co of New England Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 1.8% in the third quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock worth $671,000 after buying an additional 588 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Up 0.5%

TEVA stock opened at $31.83 on Friday. The firm’s fifty day simple moving average is $29.64 and its 200-day simple moving average is $22.67. The company has a market capitalization of $36.51 billion, a P/E ratio of 53.05, a price-to-earnings-growth ratio of 1.82 and a beta of 0.66. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $33.42.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.